Our findings of specific pathway alterations, including enriched mutations in SMAD2, ERBB4, ALK, and CTNNB1 among H/L patients, support the hypothesis that early-onset PC in this population may follow a unique molecular trajectory. Here, SMAD2 is linked to pachyonychia congenita.